Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 18, 2010

SeqWright Adds Illumina’s HiSeq 2000 to Its Sequencing Offerings

  • SeqWright acquired the Illumina HiSeq 2000 sequencing system. The firm will also utilize Illumina's scalable data-analysis software to transform billions of bases of raw sequencing data into publishable, biologically meaningful results.

    Addition of the Illumina HiSeq 2000 to SeqWright's already established Roche 454 GS FLX Titanium and Applied Biosystems SOLiD 4 sequencing platforms, along with multiple available sequence-capture and target-enrichment technologies, enables the company to offer customers the best in sequencing solutions, SeqWright points out. 

    For target enrichment, SeqWright recently introduced its RainDance Technologies capabilities as well as certified service provider status for Agilent Sureselect. SeqWright is also an authorized service provider for NimbleGen capture arrays. 

    SeqWright is based in Houston, TX, and has provided molecular biology and genomic services for over 15 years.  SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the U.S. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »